Basic Information
| LncRNA/CircRNA Name | BC200 |
| Synonyms | BCYRN1, BC200, BC200a, LINC00004, NCRNA00004 |
| Region | GRCh38_2:47335315-47335514 |
| Ensemble | ENSG00000236824 |
| Refseq | NR_001568 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | apoptosis | Drug | ||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | ovarian cancer |
| ICD-0-3 | C56.9 |
| Methods | qPCR, RNAi etc. |
| Sample | cell lines (SKOV3 and A2780) |
| Expression Pattern | down-regulated |
| Function Description | The results demonstrated that BC200 expression was reduced in ovarian cancer compared with normal ovarian tissue samples. In the SKOV3 and A2780 cells, BC200 exerted no effect on invasive or migratory ability, however, the inhibition of BC200 was demonstrated to promote cell proliferation. Additionally, it was observed that carboplatin induced BC200 expression in the cell lines, and that the inhibition of BC200 decreased the sensitivity of the cells to the drug. BC200 is therefore likely to have a tumor suppressive function in ovarian cancer by affecting cell proliferation. Furthermore, BC200 appears to serve a role in the mediation of carboplatin-induced ovarian cancer cell death |
| Pubmed ID | 26893717 |
| Year | 2016 |
| Title | Downregulation of BC200 in ovarian cancer contributes to cancer cell proliferation and chemoresistance to carboplatin |
External Links
| Links for BC200 | GenBank HGNC NONCODE |
| Links for ovarian cancer | OMIM COSMIC |